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Abstract
Influenza virus infection is a prevalent disease in humans. Antibodies against hemagglutinin have
been shown to prevent infection and hence hemagglutinin is the major constituent of current
vaccines. Antibodies directed against the highly conserved extracellular domain of M2 have also
been shown to mediate protection against Influenza A infection in various animal models. Active
vaccination is generally considered the best approach to combat viral diseases. However, passive
immunization is an attractive alternative, particularly in acutely exposed or immune compromized
individuals, young children and the elderly. We recently described a novel method for the rapid
isolation of natural human antibodies by mammalian cell display. Here we used this approach to
isolate human monoclonal antibodies directed against the highly conserved extracellular domain of
the Influenza A M2 protein. The identified antibodies bound M2 peptide with high affinities,
recognized native cell-surface expressed M2 and protected mice from a lethal influenza virus
challenge. Moreover, therapeutic treatment up to 2 days after infection was effective, suggesting
that M2-specific monoclonals have a great potential as immunotherapeutic agents against Influenza
infection.
Background
Influenza A virus still is a major cause of disease in
humans, accounting for three to five million cases of
severe illness and 250,000 - 500,000 deaths each year [1].
Efficient influenza A vaccines are available, which induce
antibodies predominantly against the two major compo-
nents of the virus membrane, hemagglutinin (HA) and
neuramidase (NA). Protection is mediated primarily by
neutralizing antibodies against HA [2,3]. Since HA under-
goes continuous change due to mutations (antigenic
drift), new antigenic variants of influenza A arise every
year requiring constant update of the vaccines. Effective
vaccination is further complicated by the occasional reas-
sortment of the segmented viral genome leading to the
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replacement of HA or NA from one subtype by another
subtype, a processs called antigenic shift [4]. Passive
immunization with monoclonal antibodies (mAbs) tar-
geting HA is very efficient [5-7], however, suffers the same
disadvantages as the current vaccines due to antigenic
shift and drift.
An ideal target for active and passive immunization strat-
egies would therefore be a conserved viral protein. The
matrix protein 2 (M2) fits the bill and has received consid-
erable attention as a potential target against influenza
infection over the past decades [8-23]. M2 is a tetrameric
ion channel [24-26] which is involved in virus uncoating
in the endosome and in virus maturation in the trans-
Golgi network [27-29]. Its 23 amino acid extracellular
domain has remained remarkably conserved in human
influenza A virus isolates over the last hundred years [30],
at least in part due to the fact that the M2 protein is co-
transcribed with the matrix protein 1 (M1) [31,32].
Whereas M2 is abundantly expressed on infected cells,
only very few M2 molecules are present in Influenza A
virus membranes [23,26]. In accordance with this, current
seasonal influenza vaccines do not induce a significant
humoral resonse against M2, and M2 specific antibodies
(administered intravenously or induced by active immu-
nization) mediate protection not by neutralizing virions,
but by eliminating infected cells by ADCC [15,22].
Passive immunization with monoclonal antibodies has
several advantages over vaccination. In particular, it
allows treating people which poorly respond to vaccines,
such as the elderly, young children or immune compro-
mised individuals. In addition, passive immunisation is
the treatment option of choice in situations where rapid
protection is crucial, such as for post-exposure treatment
or prophylaxis for the acutely exposed. A number of M2
ectodomain (M2e)-specific mAbs have been reported to
protect mice from a lethal challenge in a prophylactic set-
ting [12,17,21-23]. While these mAbs include fully
human antibodies derived from transchromosomic mice
[22], no natural human M2e-specific antibodies have
been reported to date. However, for application in human
subjects, natural human antibodies are the preferred
choice. In contrast to humanized and fully human anti-
bodies derived from phage display or transchromosomic
mice, natural human antibodies combine the advantage
of minimal immunogenicity with the smallest possible
off-target reactivity and toxicity. Furthermore, human
derived antibodies have the advantage of having gone
through the affinity maturation process, resulting in high
affinity antibodies.
We recently described a novel method for the efficient iso-
lation of antibodies from humans by mammalian cell dis-
play [33]. Here, we used this method for the isolation of
natural human antibodies directed against M2e. We dem-
onstrate that the antibodies bind M2 with high affinity
and efficiently recognize M2 from a recently isolated
H5N1 influenza A strain. The antibodies not only have
potent prophylactic activities in a mouse model of Influ-
enzy A infection, but also show efficacy in a therapeutic
setting. Thus, the natural human antibodies described
here have potential as immunotherapeutics against influ-
enza infection.
Results and Discussion
Isolation of M2e-specific human monoclonal antibodies
Human mAbs were isolated by Sindbis-mediated mam-
malian cell display [33]. First, 334 M2e-specific B cells
were isolated by FACS from the peripheral blood mono-
nuclear cells (PBMCs) of an individual with high M2e tit-
ers, using the M2e consensus peptide (M2e-cons) (Table
1) conjugated to the virus-like particle Qβ as a bait. The
immunoglobulin variable regions (VRs) of the heavy
chains (HCs) and light chains (LCs) were then amplified
by RT-PCR and assembled to single-chain antibody (scFv)
coding regions. Two separate libraries, one encoding scFv
antibodies with κ, the other with λ LCVRs, were cloned in
the Sindbis cell surface display vector pDel-SP-TM [33].
The resulting scFv-κ and scFv-λ sublibraries consisted of
1.0 × 106  and 1.1 × 106  independent transformants,
respectively. Since the library was derived from 334 cells,
it may be expected that every possible combination of
heavy and light chain is covered multiple times by the 2
million clones and, accordingly, that screening is likely to
yield antibodies containing the natural heavy and light
Table 1: M2e variants used in this study
M2 variant Abbreviation Subtype M2e (2-24) Sequence(2)
Consensus(1) M2e-cons n/a SLLTEVETPIRNEWGCRCNDSSD
A/VN/1203/04 M2e-VN H5N1 SLLTEVETPTRNEWECRCSDSSD
A/PR/8/34 M2e-PR H1N1 SLLTEVETPIRNEWGCRCNGSSD
(1) M2e consensus sequence derived from H1, H2, and H3 subtypes of human Influenza A viruses.
(2) Variations from M2e consensus sequence are shown in bold [38].Virology Journal 2009, 6:224 http://www.virologyj.com/content/6/1/224
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chain pairs. Recombinant Sindbis virus libraries were then
generated with titers of 3.4 × 107 pfu/ml and 5.7 × 107 pfu/
ml, respectively, and used to infect BHK cells at a low mul-
tiplicity of infection (MOI), to ascertain expression of a
single antibody species per infected cell.
Cells were stained for cell surface expression of M2-spe-
cific scFv using RNAse-M2e-cons or Qβ-M2e-cons conju-
gates and subjected to FACS. No M2e-specific antibodies
could be found on the surface of BHK cells infected with
the scFv-λ sublibrary. In contrast, BHK cells infected with
the scFv-κ sublibrary contained a substantial fraction of
M2e-reactive cells (typically about 0.3% of infected cells).
Three sorts were carried out with the scFv-κ library, two
using Qβ-M2e-cons (not shown) and one using RNase-
M2e-cons as bait (Figure 1A), leading to the isolation of
255 BHK cells each displaying an M2e-specific antibody.
Single cells were sorted into wells containing BHK feeder
cells and incubated for 2 to 3 days to allow for amplifica-
tion of the corresponding Sindbis virus clone. In total,
201 of the 255 wells showed signs of viral infection and
were reanalyzed for M2e binding, using RNase-M2e-cons
as a bait (Figure 1B). 130 cells showing varying degrees of
M2e binding were identified. Supernatants from wells
containing infected BHK cells displaying highly M2e-reac-
tive scFv were used to clone the corresponding scFv coding
region by RT-PCR. The large number of specific antibodies
isolated in a single screen not only illustrates the utility of
mammalian cell display [33], but also makes it an attrac-
tive alternative to other methods, typically based on clon-
ing of antibodies from single or amplified B cell clones
[34,35], or from EBV-immortalized memory B cells [36].
Since the protective potential of M2e-specific antibodies
depends on ADCC [15], the scFv antibodies were fused to
the Fc region of mouse IgG2c (msFc-γ2c), allowing in vivo
efficacy testing in a mouse model of influenza. All scFv-
msFc-γ2c fusion proteins were expressed in HEK 293T
cells, using an Epstein Barr virus (EBV)-based episomal
expression vector. Binding of scFv-msFc-γ2c antibodies to
M2e was confirmed by ELISA, using supernatants from
transiently transfected cells (not shown). Clones D005,
E040 and F052 were selected for further analysis,
expressed in HEK-293T cells and purified by affinity chro-
matography. The three antibodies were expressed at high
levels, with yields of 20 to 40 mg per liter. These yields are
in the same range as the ones we previously reported for
Qβ- and Nicotine-specific human antibodies [33], dem-
onstrating that the mammalian cell display method con-
(A) Isolation of BHK cells displaying M2e-specific scFv Figure 1
(A) Isolation of BHK cells displaying M2e-specific scFv. BHK cells were infected with the scFv-κ Sindbis virus library at 
an MOI of 0.1 and stained as indicated. Sindbis-positive cells displaying M2e-specific scFv in the upper right quadrant were 
sorted. Note that cells in the lower right quadrant (M2e-positive but Sindbis-negative) are infected with a replication-defective 
form of the virus. (B) Rescreening for M2e-specific antibodies. Two to three days after sorting, BHK cells in wells showing signs 
of viral infection were analyzed for binding to RNAse-M2e. Nine representative samples are shown, including cells showing 
strong binding (D005, E040, F052), intermediate binding (D036, E012, F058), or no binding (D021, E016, F080).
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sistently yields antibodies that are highly expressed in
mammalian cells.
In vitro analysis of M2e-specific monoclonal antibodies
We next determined the affinity of D005, E040, and F052
for M2e. To this end, the dissociation constants (Kd) of
antibody binding to M2e-cons in solution were deter-
mined using an ELISA-based method [37] (Figure 2A).
The scFv-msFc-γ2c antibodies were found to bind M2e-
cons peptide with high affinity, with Kd values of 4-5 nM
(Figure 2A).
In a next set of experiments the ability of the antibodies to
cross-react with a peptide covering M2e from a recent
Influenza A H5N1 isolate (A/VN/1203/2004) was
assessed by ELISA. The sequence of the peptide used for
coating (M2e-VN) is shown in Table 1. Thus, ELISA plates
were coated with M2e-cons or M2e-VN peptide conju-
gated to RNAse A, and serial dilutions of the different
scFv-msFc-γ2c antibodies were applied. Significantly, each
of the antibodies bound both peptides to a similar extent,
with EC50 values of 5-10 ng/ml (45-90 pM), indicating
that they efficiently crossreact with H5N1-derived M2e.
Finally, binding of the antibodies to native, cell surface
M2 was investigated (Figure 2C). To this end, a clone of
L929 cells expressing full-length M2 derived from Influ-
enza A/PR/8/34 (H1N1) was generated (L929-M2#E9).
The sequence for the extracellular domain of the M2 is
shown in Table 1 (M2e-PR). The cells were stained with
Binding properties of M2e-specific scFv-msFc-γ2c antibodies Figure 2
Binding properties of M2e-specific scFv-msFc-γ2c antibodies. (A) Determination of affinity. The dissociation constants 
(Kd) of antibody binding to M2e-cons peptide in solution was determined by Friguet ELISA. (B) Binding to H5N1 Influenza A 
derived M2e. Antibody binding to the indicated RNAse-M2e conjugates was measured at different concentrations by ELISA. 
(C) Binding to cell surface M2. L929-M2#E9 cells, a clone of L929 cells expressing full-length M2 derived from mouse-adapted 
H1N1 Influenza A PR/8/34, were stained with the indicated antibodies and analyzed by FACS. Bold lines, 0.5 μg/ml; solid lines, 
60 ng/ml; dotted lines, secondary antibody alone.
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increasing concentrations of D005, E040 or F052. A con-
centration-dependent staining of the cells was observed,
demonstrating that each of the antibodies is capable of
recognizing cellular, native M2 protein. In agreement with
the ELISA results, the three antibodies showed similar
binding to L929 cells expressing M2.
Prophylactic activity of M2e-specific antibodies against 
influenza virus infection
We next explored the clinical potential of the antibodies
by investigating their protective activity in an in vivo
model of influenza A infection. This model reflects most
aspects of Influenza infection in humans and is therefore
routinely used to assess the efficacy of anti-viral agents.
Groups of mice were passively immunized i.p. with 500
μg scFv-msFc-γ2c antibodies D005, E040 or F052, while a
control group received the same amount of mouse IgG.
Two days later, animals were infected intranasally with a
lethal dose (4 × LD50) of mouse adapted (m.a.) influenza
A/PR/8/34 and monitored for morbidity and mortality
(Figure 3). Control mice treated with mouse IgG showed
a dramatic drop in body temperature and substantial
weight loss within few days after infection and and had to
be euthanized on days 7 or 8 due to the severity of the
symptoms (Figure 3C). In contrast, all animals that had
been treated with M2-specific antibodies survived the
lethal challenge, hardly developed any fever and only dis-
played a transient weight loss (Figure 3A and 3B).
Titration of M2e-specific antibody D005
We next set out to determine the amount of antibody
required to achieve protection in a prophylactic setting in
mice. To this end, groups of mice were treated with
decreasing amounts of scFv-msFc-γ2c D005 or, as a con-
trol, with 200 μg of mouse IgG. Two days later, animals
were infected with a lethal dose of m.a. influenza A/PR/8/
34 and monitored for 21 days (Figure 4A). As expected,
control mice quickly succumbed to the infection and all
had to be euthanized due to the severity of the disease
within less than two weeks after challenge. In contrast, all
animals that had received at least 20 μg of D005 antibody
survived the challenge. Even at the lowest dose of 6 μg
D005, half of the mice recovered and survived infection,
indicating that the M2-specific antibody is a potent pro-
phylactic agent.
Therapeutic activity of M2e-specific antibody D005
In view of the potent prophylactic activity of D005, the
antibody's ability to control an established viral infection
was tested next (Figure 4B). Thus, groups of mice were
infected with a lethal dose of m.a. influenza A/PR/8/34
and treated with a single injection of 200 μg scFv-msFc-
γ2c D005 1, 2 or 3 days after challenge. Animals treated
with 200 μg D005 or mouse IgG two days prior to the
infection served as positive and negative controls respec-
tively. In accordance with the results above all mice
treated with the control antibody succumbed to the dis-
ease, whereas all mice that had received the D005 anti-
body prophylactically survived the lethal challenge.
Importantly, almost all animals which had been treated
therapeutically within two days after infection survived
the challenge. Even animals that had been treated 3 days
post infection appeared to withstand the infection longer
than the control group.
Recently, the M2-specific human antibody Z3G1 has been
reported to show therapeutic activity in mice [22]. How-
ever, multiple injections of Z3G1 starting as early as 5 h
after infection were required for full protection. Antibody
D005 compares favorably to this, since it was fully protec-
tive with a single injection at day 1 and still showed some
protection when administered 3 days after challenge.
Taken together, these data indicate that treatment with
antibody D005, in addition to its potential as pre-expo-
sure prophylaxis, may also be used therapeutically at the
early stages of infection.
Prophylactic activity of fully human IgG1k-D005
Given the intended use of the M2e-specific antibody in
humans, D005 was produced as a fully human IgG1 in
293T cells using an EBV-based episomal expression sys-
tem. Similar to the scFv-msFc-γ2c antibodies, IgG1-D005
was expressed at high levels in mammalian cells and
yielded approximately 70 mg per liter culture supernatant.
To evaluate its protective activity in the influenza A mouse
model, IgG-D005 was compared to its scFv-msFc-γ2c
counterpart. Thus, groups of mice were treated with equi-
molar amounts of IgG1-D005, scFv-D005-msFc-γ2c, or
human IgG. Two days later, animals were infected with a
lethal dose of influenza A/PR/8/34 and closly monitored
for 16 days (Figure 5). Mice treated with control human
IgG displayed a dramatic drop in body temperature and
weight loss and had to be euthanized between 8 and 11
days after infection due the severity of the symptoms. In
contrast, all animals treated with M2-specific antibodies
survived the lethal challenge, hardly experienced any fever
and showed only a transient drop in body weight. Thus,
D005 was protective both as a scFv-msFc-γ2c fusion pro-
tein and as a fully human IgG1, indicating that the human
antibody was able to recruit effector functions in the
mouse system and that IgG-D005 may be used as a valua-
ble prophylactic or therapeutic agent in humans.
Conclusions
Human antibodies specific for the Influenza A M2 protein
were isolated and shown to have potent prophylactic and
therapeutic activity in a mouse model. This underscores
the utility of Sindbis-based mammalian cell display for
the isolation of natural human antibodies with therapeu-
tic potential.Virology Journal 2009, 6:224 http://www.virologyj.com/content/6/1/224
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Effect of M2-specific scFv-msFc-γ2c antibodies on Influenza-induced morbidity and mortality Figure 3
Effect of M2-specific scFv-msFc-γ2c antibodies on Influenza-induced morbidity and mortality. Mice were treated 
with 500 μg of the indicated antibody on day -2, infected with Influenza A virus PR8 on day 0, and body temperature (A), 
weight (B) and survival (C) were monitored over time.
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Dose response and therapeutic activity of scFv-msFc-γ2c D005 Figure 4
Dose response and therapeutic activity of scFv-msFc-γ2c D005. (A) Dose titration. Mice were treated with the indi-
cated amounts of antibody on day -2, infected with Influenza A virus PR8 on day 0, and survival was monitored for 21 days. (B) 
Therapeutic setting. Mice were infected with Influenza A virus PR8 on day 0, treated with 200 μg of the antibody on the indi-
cated days, and survival was monitored for 21 days. Control, 200 μg mouse IgG on day -2.
  Beerli et al. 
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Effect of M2-specific antibody D005 on Influenza-induced morbidity and mortality Figure 5
Effect of M2-specific antibody D005 on Influenza-induced morbidity and mortality. Mice were treated with 144 μg 
scFv-msFc-γ2c, 200 μg hIgG1 or 200 μg control human IgG (Ctr. Ab) on day -2, infected with Influenza A virus PR8 on day 0, 
and body temperature (A), weight (B) and survival (C) were monitored on the indicated days.
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Methods
Identification of M2-specific antibodies by mammalian cell 
display
Peripheral blood mononuclear cells (PBMC) were iso-
lated from 10 ml of heparinized blood by Ficoll gradient.
PBMC were pre-incubated with Alexa 647 nm-labeled Qβ
and human gamma globulin (Jackson ImmunoResearch)
and then stained with: (1) M2e coupled to Qβ in combi-
nation with a Alexa 488 nm-labeled Qβ-specific mouse
mAb, as well as the M2-specific mouse mAb 14C2
(Abcam) in combination with FITC-labeled donkey anti-
mouse IgG antibody (Jackson ImmunoResearch); (2) PE-
labeled mouse anti-human IgM, mouse anti-human IgD,
mouse anti-human CD14, and mouse anti-human CD3
antibodies (all BD Biosciences/Pharmingen); and (3) PE-
TexasRed-labeled mouse anti-human CD19 antibody
(Caltag Laboratories). After staining, cells were washed
and filtered, and 334 M2-specific B cells (FL1-positive,
FL2-negative, FL3-positive, FL4-negative) were sorted on a
FACSVantage® SE flow cytometer (Becton Dickinson).
A Sindbis virus-based scFv cell surface display library was
produced from antigen-specific B cells as described [33].
BHK cells were infected with the Sindbis library and cells
displaying M2-specific scFv antibodies were isolated using
M2e coupled to RNase A in combination with an RNase-
specific rabbit polyclonal antibody (Abcam) and a FITC-
labeled donkey anti-rabbit IgG antibody (Jackson Immu-
noResearch). Alternatively, cells displaying M2-specific
scFv antibodies were isolated using Qβ-M2e in combina-
tion with M2-specific mouse mAb 14C2 (Abcam) and
FITC-labeled donkey anti-mouse IgG antibody (Jackson
ImmunoResearch). Each cell was sorted into a well of a
24-well plate containing 50% confluent BHK feeder cells.
Upon virus spread (2 days post sorting), the infected cells
were tested by FACS analysis for M2-binding to identify
virus clones encoding M2-specific scFv antibodies.
Expression and purification of scFv antibodies
Fusion proteins were generated carrying an N-terminal
human scFv fused to a C-terminal mouse Fc-γ2c domain.
Thus, scFv coding regions were PCR amplified from Sind-
bis virus-containing supernatants by RT-PCR, digested
with the restriction endonuclease Sfi1 and cloned into the
expression vector pCEP-SP-Sfi-msFc-γ2c. This vector is a
derivative of the episomal mammalian expression vector
pCEP4 (Invitrogen), carrying the Epstein-Barr Virus repli-
cation origin (oriP) and nuclear antigen (encoded by the
EBNA-1 gene) to permit extrachromosomal replication,
and contains a puromycin selection marker in place of the
original hygromycin B resistance gene. The resulting plas-
mids drive expression of scFv-msFc-γ2c fusion proteins
under the control of a CMV promoter.
Fully human γ1 heavy chain and κ light chain coding
regions were generated by total gene synthesis (GeneArt
AG, Regensburg, Germany) and combined into the EBNA-
based expression vector pCB15 essentially as described
[33].
Expression of the scFv-msFc-γ2c fusion proteins, as well as
fully human IgG1κ antibody was done by transfecting the
expression vectors into HEK-293T cells, using Lipo-
fectamin Plus (Invitrogen). For large scale production and
purification, stable protein-expressing cells were enriched
by selection in the presence of 1 μg/ml puromycin
(Sigma). Pools of resistant cells were maintained in
serum-free medium on Poly-L-Lysine coated dishes or in
roller bottles for up to 3 weeks. Supernatants containing
the respective antibodies were collected twice a week and
filtered through a 0.22 μM Millex GV sterile filter (Milli-
pore). Both types of antibodies were purified by affinity
chromatography over a protein A-Sepharose column (GE
healthcare).
ELISA analysis
ELISA plates (96 well MAXIsorb, NUNC) were coated with
RNAse-M2e-cons or RNAse-M2e-VN at a concentration of
4 μg/ml in coating buffer (0.1 M NaHCO3, pH 9.6) for
one hour at 37°C. The plates were then washed with wash
buffer (PBS/0.05% Tween) and blocked for 2 h at 37°C
with 3% BSA in wash buffer. The plates were then washed
again and incubated with 3-fold serial dilutions of scFv-
msFc-γ2c in wash buffer containing 1% BSA. Plates were
incubated for 2 h at room temperature and then exten-
sively washed with wash buffer. Specifically bound anti-
bodies were then detected with HRPO-labeled, Fcγ-
specific, goat anti-mouse IgG antibody (Jackson Immu-
noResearch Laboratories). After extensive washing with
wash buffer, plates were developed with a 0.4 mg/ml solu-
tion of 1, 2-ortho-phenylenediamine dihydrochloride
(OPD) in citric acid buffer (35 mM citric acid, 66 mM
Na2HPO4, pH 5.0) containing 0.01% H2O2. After 10 min
the reaction was stopped with a 5% solution of H2SO4 in
H2O, and plates were read at 450 nm on an ELISA reader
(Biorad Benchmark).
Affinity measurement by Friguet ELISA
A 10 ng/ml solution of, respectively, scFv-D005-msFc-γ2c,
scFv-E040-msFc-γ2c or scFv-F052-msFc-γ2c, was incu-
bated in the presence of different concentrations of M2e-
cons peptide (3-fold serial dilutions corresponding to 10
nM to 0.17 pM) in PBS/1% BSA. After 2 h at room temper-
ature, free antibody was detected by a classical ELISA sim-
ilar to the one described above. For this, ELISA plates that
had been coated with RNAse-M2e-cons conjugate at a
concentration of 20 ng/ml at 4°C overnight were washed
with wash buffer (PBS/0.05% Tween) and blocked for 2 h
at 37°C with 3% BSA in wash buffer. The plates were thenVirology Journal 2009, 6:224 http://www.virologyj.com/content/6/1/224
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washed again and incubated with the solution binding
reactions for 30 min at room temperature. After extensive
washing with wash buffer, bound scFv-Fcγ2c fusion pro-
teins were detected by a 1 h incubation at room tempera-
ture with a HRPO-labeled, Fcγ-specific, goat anti-mouse
IgG antibody (Jackson ImmunoResearch Laboratories).
After extensive washing with wash buffer, plates were
developed as described above. The Kd values were deter-
mined as the EC50 of the ELISA signal as a function of the
M2e-cons peptide concentration present in the solution
binding reaction.
Mouse model of Influenza A infection
Prophylactic and therapeutic activity of antibodies was
tested in a mouse model of Influenza A infection. Thus,
six weeks old female C57BL/6 mice (6 per group) were
infected intranasally with a lethal dose of mouse-adapted
(m.a.) influenza A virus PR8 (4 × LD50), followed by
close monitoring of weight-loss and fever (twice daily at
peak of infection). Antibodies were injected intraperito-
neally either 2 days before (prophylactic setting) or 1 to 3
days after infection (therapeutic setting). One day later,
mice were bled in order to verify the presence of the anti-
bodies in the blood by ELISA (not shown). Antibodies
were readily detectable in the sera of all mice, except for
one mouse receiving 500 μg scFv-D005-msFc-γ2c (Figure
3) and one mouse receiving 60 μg scFv-D005-msFc-γ2c
(Figure 4A); these mice were subsequently removed from
the analysis. All animal experiments were carried out in
accordance with protocols approved by the Swiss Federal
Veterinary Office. Animals whose body temperature
reached 30°C were considered moribund and had to be
euthanized immediately due to abortion criteria defined
by the Veterinary Office.
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